Biosimilars and Novel Insulins
Conclusions:
Biosimilar insulins have comparable PK-PD profiles and equivalent efficacy and safety to original insulins at a lower price, making them available for more people with diabetes. Faster aspart is the first ultrafast-acting insulin. New upcoming clinical trials and more clinical experience with faster aspart will show the real potential of this new insulin.
Source: American Journal of Therapeutics - Category: Drugs & Pharmacology Tags: Therapeutic Advances Source Type: research
More News: Clinical Trials | Databases & Libraries | Diabetes | Diabetes Type 1 | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Humalog | Insulin | Lantus